SUPRAXONE 1G (CEFTRIAXONE POWDER FOR SOLUTION FOR INJECTIONINFUSION)

国: マレーシア

言語: 英語

ソース: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

有効成分:

CEFTRIAXONE SODIUM

から入手可能:

PHARMEX SDN BHD

INN（国際名）:

CEFTRIAXONE SODIUM

パッケージ内のユニット:

10 Vials

製:

Zhuhai United Laboratories (Zhongshan) Co. Ltd.

製品の特徴

1
SUPRAXONE 1G (CEFTRIAXONE POWDER FOR
SOLUTION FOR INJECTION/INFUSION)
Please read the package insert carefully
[DESCRIPTION]
White or off-white crystalline powder, odorless.
The diluents used to reconstitute the drug product include sterile
water for injection, lidocaine
hydrochloride 1%, sodium chloride injection 0.9% and dextrose
injection 5%. After
reconstitution, the solution should be clear and range in colour from
pale yellow to amber,
depending on the concentration and length of storage. The coloration
of the solutions is of no
significance for the efficacy or tolerance of the drug
[INDICATIONS]
Infections caused by pathogens sensitive to Supraxone, e.g.:
- sepsis;
- meningitis;
- disseminated Lyme borreliosis (early and late stages of the
disease);
- abdominal infections (peritonitis, infections of the biliary and
gastrointestinal tracts);
- infections of the bones, joints, soft tissue, skin and of wounds;
- infections in patients with impaired defense mechanisms;
- renal and urinary tract infections;
- respiratory tract infections, particularly pneumonia, and ear, nose
and throat infections;
- genital infections, including gonorrhea.
And perioperative prophylaxis of infections.
[DOSAGE AND ADMINISTRATION]
_Standard dosage _
_Adults and children over 12 years_
The usual dosage is 1–2 g of Supraxone _once daily_ (every 24
hours). In severe cases or in
infections caused by moderately sensitive organisms, the dosage may be
raised to 4 g, once
daily.
_Duration of therapy _
The duration of therapy varies according to the course of the disease.
As with antibiotic
therapy in general, administration of Supraxone should be continued
for a minimum of 48-72
hours after the patient has become afebrile or evidence of bacterial
eradication has been
obtained.
_Combination therapy _
Synergy between Supraxone and aminoglycosides has been demonstrated
with many gram-
negative
bacteria
under
experimental
conditions.
Although
enhanced
activity
of
such
combinations is not always predictable, it should be considered in
sev